Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice
Research output: Contribution to journal › Journal article › Research › peer-review
Breast cancer frequently leads to incurable bone metastasis. Essential requirements for the development of bone metastasis are cell-cell and cell-matrix interactions, release of bioactive growth factors and cytokines, and removal of large amounts of bone matrix. Matrix metalloproteinases (MMPs) play an important role in all of these processes, but the possibility of using synthetic MMP inhibitors to decrease bone metastasis has received little attention.
| Original language | English |
|---|---|
| Journal | Clinical Cancer Research |
| Volume | 8 |
| Issue number | 6 |
| Pages (from-to) | 1932-9 |
| Number of pages | 8 |
| ISSN | 1078-0432 |
| Publication status | Published - 2002 |
- Animals, Antineoplastic Agents, Bone Neoplasms, Breast Neoplasms, Cell Survival, Dipeptides, Female, Gene Therapy, Humans, Matrix Metalloproteinases, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Invasiveness, Osteolysis, Phenylalanine, Protease Inhibitors, Thiophenes, Transfection, Transplantation, Heterologous, Tumor Cells, Cultured
Research areas
ID: 38426485